HomeCompareCGA vs PFE

CGA vs PFE: Dividend Comparison 2026

CGA yields 101.01% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CGA wins by $4.01M in total portfolio value
10 years
CGA
CGA
● Live price
101.01%
Share price
$1.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.06M
Annual income
$1,377,317.85
Full CGA calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CGA vs PFE

📍 CGA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCGAPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CGA + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CGA pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CGA
Annual income on $10K today (after 15% tax)
$8,585.86/yr
After 10yr DRIP, annual income (after tax)
$1,170,720.17/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, CGA beats the other by $1,148,400.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CGA + PFE for your $10,000?

CGA: 50%PFE: 50%
100% PFE50/50100% CGA
Portfolio after 10yr
$2.05M
Annual income
$701,788.28/yr
Blended yield
34.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CGA
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-0.6
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CGA buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCGAPFE
Forward yield101.01%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4.06M$49.6K
Annual income after 10y$1,377,317.85$26,258.71
Total dividends collected$3.63M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: CGA vs PFE ($10,000, DRIP)

YearCGA PortfolioCGA Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$20,801$10,101.01$9,153$693.39+$11.6KCGA
2$41,894$19,636.56$8,593$849.25+$33.3KCGA
3$81,787$36,961.14$8,336$1,066.78+$73.5KCGA
4$154,950$67,437.20$8,437$1,384.80+$146.5KCGA
5$285,201$119,404.39$9,013$1,875.40+$276.2KCGA
6$510,563$205,398.01$10,306$2,680.72+$500.3KCGA
7$889,948$343,645.86$12,820$4,101.38+$877.1KCGA
8$1,512,057$559,812.91$17,673$6,826.70+$1.49MCGA
9$2,506,821$888,920.19$27,543$12,591.86+$2.48MCGA
10$4,059,617$1,377,317.85$49,560$26,258.71+$4.01MCGA

CGA vs PFE: Complete Analysis 2026

CGAStock

China Green Agriculture, Inc., through its subsidiaries, engages in the research, development, production, and sale of various fertilizers and agricultural products in the People's Republic of China. The company operates through four segments: Jinong, Gufeng, Yuxing, and Sales VIEs. Its fertilizer products comprise humic acid-based compound fertilizers, blended fertilizers, organic compound fertilizers, slow-release fertilizers, highly concentrated water-soluble fertilizers, and mixed organic-inorganic compound fertilizers, as well as develops, produces, and distributes agricultural products, such as fruits, vegetables, flowers, and colored seedlings. The company markets its fertilizer products to private wholesalers and retailers of agricultural farm products. It sells its decorative flowers to end-users, such as flower shops, luxury hotels, and government agencies; fruits and vegetables to supermarkets and upscale restaurants; and seedlings to city planning departments. As of June 30, 2021, the company operated a network of 1,756 distributors covering 22 provinces, 4 autonomous regions, and 4 central government-controlled municipalities in China. It also exports its products through contracted distributors to various countries, including India and Africa. China Green Agriculture, Inc. was incorporated in 1987 and is based in Xi'an, the People's Republic of China.

Full CGA Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CGA vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CGA vs SCHDCGA vs JEPICGA vs OCGA vs KOCGA vs MAINCGA vs JNJCGA vs MRKCGA vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.